Welcome to our dedicated page for Ikena Oncology SEC filings (Ticker: IKNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech like Ikena Oncology isn’t easy—hundreds of pages detail complex signaling science, shifting R&D spend, and cash runway projections. If you have ever asked, “Ikena Oncology SEC filings explained simply” or searched for “understanding Ikena Oncology SEC documents with AI,” you already know the challenge.
Stock Titan’s platform turns that challenge into clarity. Our AI instantly summarizes every submission—whether it’s the Ikena Oncology annual report 10-K simplified for pipeline updates, an Ikena Oncology quarterly earnings report 10-Q filing that breaks down trial costs, or an Ikena Oncology 8-K material events explained announcement about new data read-outs. Real-time feeds push Ikena Oncology Form 4 insider transactions real-time alerts so you never miss executive stock moves. Need granular detail? Interactive layers link straight to footnotes covering collaboration revenue or milestone payments.
Here’s what you can track in one place:
- “Ikena Oncology insider trading Form 4 transactions” including option exercises and open-market buys
- “Ikena Oncology proxy statement executive compensation” to compare pay with clinical progress
- “Ikena Oncology earnings report filing analysis” that benchmarks quarterly burn rate
- “Ikena Oncology executive stock transactions Form 4” patterns ahead of data releases
Every document arrives from EDGAR within seconds, then our AI surfaces trial timelines, Hippo and RAS program milestones, and any dilution risks buried in prospectus supplements. Stop scrolling through PDFs—get the biotech intelligence you need, the moment it’s filed.
Form 4 – ImageneBio, Inc. (ticker IKNA)
Chief Financial Officer Jotin Marango disclosed merger-related equity adjustments tied to the 25 Jul 2025 closing of ImageneBio’s combination with Inmagene Biopharmaceuticals (formerly Ikena Oncology). On 28 Jul 2025 the CFO received 15,776 common shares (code A) issued in exchange for former Ikena options. To cover withholding taxes, 4,630 shares were automatically surrendered at $17.16 per share (code F), leaving a direct holding of 11,146 shares.
All legacy Ikena stock options were cancelled (code D): 181,000; 105,000; and 397,199 options, totalling 683,199 contracts. Following the transactions Marango holds no derivative securities.
The filing reflects mandatory conversion mechanics of the merger rather than discretionary trading, so its informational value is limited. Nonetheless, the CFO now has an equity stake in the combined company, aligning interests with shareholders.
Amendment No. 1 to Schedule 13D shows that BML Investment Partners, L.P. and its managing member, Braden M. Leonard, have materially reduced their position in Ikena Oncology (IKNA).
- Open-market sales between 16-22 Jul 2025 totalled 1,459,110 shares at $1.20-$1.30 per share.
- Current ownership: BML Investment Partners 215,832 shares; Leonard 5,000 shares; aggregate 220,832 shares.
- The cover page lists the stake as 1.9 % of outstanding shares; Item 5 cites 8.35 %, signalling an internal discrepancy.
The filing states the shares were acquired for investment purposes, the group is now below the 5 % reporting threshold, and it has no present plans to influence corporate actions. Future trades may occur depending on market conditions. No contracts or arrangements with other parties were disclosed.
ImageneBio, Inc. (formerly Ikena Oncology, Inc.) has filed an 8-K to confirm that on 25 Jul 2025 it closed the previously announced merger with Cayman-based Inmagene Biopharmaceuticals. Two wholly owned Cayman merger subsidiaries were used to combine Inmagene into the Delaware parent, leaving Inmagene as a wholly owned subsidiary.
Immediately after closing, the registrant changed its corporate name to “ImageneBio, Inc.” and updated its Nasdaq listing to the new ticker IMA. The company furnished, under Item 7.01 (Reg FD), a press release (Exhibit 99.1) announcing completion of the transaction; the release is incorporated by reference but not deemed “filed.” No consideration details, pro-forma financials or other quantitative information are provided in this report.
FAQ
What is the current stock price of Ikena Oncology (IKNA)?
What is the market cap of Ikena Oncology (IKNA)?
